A Study of Axitinib in Advanced Carcinoid Tumors

Inclusion Criteria: * Locally unresectable or metastatic well-and moderately-differentiated (low- or intermediate- grade) neuroendocrine tumors of the aerodigestive tract (e.g. foregut, midgut, and hindgut) and unknown primary site as well as rare primary sites (renal, ovarian, thymic, hepatic); Otherwise known as typical or atypical carcinoid tumors * Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) Criteria * Functional or nonfunctional tumors allowed * Evidence of progressive disease within 12 months of study entry * Adequate hepatic function: total bilirubin ≤1.5 x upper limit of normal (ULN)mg/dl; aspartic transaminase (AST) ≤2.5 x ULN (≤5 x ULN if attributable to liver metastases) * Adequate renal function: serum creatinine ≤ 1.5 x ULN * Adequate bone marrow function: absolute neutrophil count ≥ 1,500/mm³; platelets ≥75,000/mm³ * Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels ≤1.5 x ULN (unless patients receiving coumadin anticoagulation in which case a stable international normalization ration (INR) of 2-3 is required). * Urine protein \<2+proteinuria (or \<2 g proteinuria /24 hr) * Prior somatostatin-analog therapy required in patients with midgut carcinoid tumors * Minimum 4 weeks since completion of prior treatment (investigational or other). Prior treatment with chemotherapy, radiotherapy, hepatic artery embolization, surgery or other therapeutic agents is allowed. * Treatment related toxicity should have r…